Literature DB >> 18462360

Use of a BRCA1 peptide validates MS110 as a BRCA1-specific antibody in immunohistochemistry.

A Alamshah, R Springall, C E Gillett, E Solomon, J R Morris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18462360     DOI： 10.1111/j.1365-2559.2008.03049.x

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


× No keyword cloud information.
  2 in total

1.  Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours.

Authors:  Roy Milner; Helen Wombwell; Sonia Eckersley; Donna Barnes; Juli Warwicker; Erica Van Dorp; Rachel Rowlinson; Simon Dearden; Glen Hughes; Chris Harbron; Bob Wellings; Darren Hodgson; Chris Womack; Neil Gray; Alan Lau; Mark J O'Connor; Catherine Marsden; Alexander J Kvist
Journal:  Virchows Arch       Date:  2013-01-25       Impact factor: 4.064

2.  A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.

Authors:  Jemima J Dorairaj; David W Salzman; Deirdre Wall; Tiffany Rounds; Carina Preskill; Catherine A W Sullivan; Robert Lindner; Catherine Curran; Kim Lezon-Geyda; Terri McVeigh; Lyndsay Harris; John Newell; Michael J Kerin; Marie Wood; Nicola Miller; Joanne B Weidhaas
Journal:  BMC Cancer       Date:  2014-06-10       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.